Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-06-04

Clinical Trial Update: Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of RPL554 in COPD patients has been completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RPL554 (RPL554)

Snippet

Sponsor: Verona Pharma plc | Conditions: COPD | Phase 2 | Status: COMPLETED | Results posted: 2019-06-04